Notices of Registration - 2000[Federal Register: May 23, 2000 (Volume 65, Number
100)] DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By notice dated February 10, 2000, and published in the Federal Register on February 17, 2000, (65 FR 33), Novartis Pharmaceutical Corporation, 59 Route 10, East Hanover, New Jersey 07926, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of methylphenidate (1724), a basic class of controlled substance listed in Schedule II. The firm plans to manufacture finished product for distribution to its customers. DEA has considered the factors in title 21, United
States Code, section 823(a)
and determined that the registration of Novartis Pharmaceutical
Corporation to manufacture methylphenidate is consistent with the public
interest at this time. DEA has investigated Novartis Pharmaceutical
Corporation on a regular basis to ensure that the company's continued
registration is consistent with the public interest. These
investigations have included inspection and testing of the company's
physical security systems, audits of the company's records, verification
of the company's compliance with state and local laws, and a review of
the company's background and history. Therefore, pursuant to 21
U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant
Administrator, Office of Diversion Control, hereby orders that the
application submitted by the above firm for registration as a Dated: May 12, 2000. John H. King, [FR Doc. 00-12841 Filed 5-22-00; 8:45 am]
Registration
Support
|